Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06698458 · ClinicalTrials.gov registry record · NA
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
A NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Alpha Tau Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 15
- Study locations
NCT06698458: Recruiting NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, sponsored by Alpha Tau Medical.
NCT06698458 is a NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma that is actively recruiting participants, run by Alpha Tau Medical. The registered enrollment target is 30 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (92% lower). The trial reports 15 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06698458, a NA study of Pancreatic Cancer and Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Alpha Tau Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classification of AEs will be done according to CTCAE V5. The secondary objectives of the study are to: * Assess efficacy of the Alpha DaRT sources in combination with chemotherapy, determined by overall and progression-free survival. * Assess pain control * Assess rate of surgical resection in Cohort 1.
Primary Outcome
The primary endpoint is the incidence , rate and severity of treatment- emergent Adverse Events (TEAS) graded according to CTCAE V6.0.
Conditions Studied
Interventions
- DEVICE Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Study Locations (15)
New York
- Bassett Healthcare Network - Cooperstown
- NYU Langone Health - New York
- Lenox hill Hospital - New York
- Montefiore Medical Center - The Bronx
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- City of Hope - Goodyear
- Honor Health - Scottsdale
Texas
- Texas Oncology - Houston
- Baylor College of Medicine - Houston
- University Cancer and Diagnostic - Houston
California
- Cedars-Sinai - Los Angeles
Florida
- Advent Health Cancer Institute - Orlando
Georgia
- Emory University - Atlanta
Quebec
- Jewish General Hospital - Montreal
Other
- Hadassah Ein Kerem - Jerusalem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06698458 shows while recruiting
NCT06698458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (92% lower).
The record links to 3 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) is the first listed.
NCT06698458 lists 15 locations in 8 states (New York, Arizona, Texas).
Frequently Asked Questions
What is clinical trial NCT06698458 about?
NCT06698458 is a clinical study titled "Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer". This is a multi-center clinical study enrolling up to 30 participants (15 patients in each cohort). The primary objective of the study is to evaluate the safety of Alpha DaRT in combination with chemotherapy, based on the cumulative incidence rate, severity and outcome of device related AEs. Classif...
What is the current status of trial NCT06698458?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-06-17. Estimated completion is 2026-12.
What conditions does trial NCT06698458 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT06698458?
The interventions under investigation include: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT) (DEVICE).
Who is sponsoring clinical trial NCT06698458?
This trial is sponsored by Alpha Tau Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06698458 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06698458's enrollment target sits among peer trials
30 189th of 278 higher than 83 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
-
Resistance Exercise Combined With Protein Supplementation in People With Pancreatic Cancer: The RE-BUILD Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI